Bio-Bridge Announces Favorable Safety and Immunogenicity Results From Pre-clinical Study of Oral HIV Vaccine; Animal Studies Su

Bio-Bridge Science, Inc. (OTCBB: BGES), a developer of
vaccines with broad preventative and therapeutic applications, today
announced that the Beijing Institute of Radiation Medicine has
notified the Company that it has completed the planned pre-clinical
safety and immunogenicity studies for Bio-Bridge's oral HIV vaccine.
In early February, Bio-Bridge Science received encouraging initial
results of the pre-clinical trials. Final results show no toxicity was
observed in the animals orally administered with the HIV vaccine.
There is no indication that vaccine DNA integrates into host genome
and passes through placenta barrier. The immunogenicity study in
monkeys shows that the vaccine induces HIV-1 gp41-specific serum
antibodies (IgG) and intestinal and vaginal antibodies (sIgA). The
sera, intestinal and vaginal washings neutralize HIV-1 primary isolate
in vitro. The vaccine also induces HIV-1 Gag-specific T cells in the
vaccinated monkeys.
   "We are very pleased that the Beijing Institute of Radiation
Medicine has reported favorable safety and immunogenicity data on our
oral HIV vaccine," commented Liang Qiao, M.D., Chairman and CEO of
Bio-Bridge Science. "It is a major milestone in the development of our
HIV vaccine."
   Based on these favorable results, the company is expected to file
application for clinical trials with the Chinese FDA in the near
future.

   About Bio-Bridge Science:

   Bio-Bridge Science is a biotechnology firm focused on the
development of vaccines with broad therapeutic and preventive
applications. Through its wholly owned subsidiary in Beijing,
Bio-Bridge is developing a promising new HIV Vaccine that is expected
to enter clinical trials this year in China. The vaccine, based on
exclusive technology co-developed by CEO Liang Qiao, an associate
professor at Loyola University Chicago's Strich School of Medicine,
targets infection in mucosal tissues, the first type of tissue
attacked by HIV. The Chinese government, mindful of the rapid
expansion of AIDS in China has, through the "Green Mile Policy", acted
to expedite the approval of domestically produced HIV Vaccines.
Bio-Bridge Science's GMP facility will also be used to develop
vaccines against cervical cancer and colon cancer under the same
technology platform as the HIV vaccine.

   Forward Looking Statements

   This press release contains forward-looking statements as defined
by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. These statements are subject to
uncertainties and risks including, but not limited to, product and
service demand and acceptance, changes in technology, economic
conditions, the impact of competition and pricing, government
regulation, and other risks defined in this document and in statements
filed from time to time with the Securities and Exchange Commission.
All such forward-looking statements, whether written or oral, and
whether made by or on behalf of the company, are expressly qualified
by these cautionary statements and any other cautionary statements
which may accompany the forward-looking statements. In addition, the
company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date hereof.
Please refer to SEC filings for additional information and
accompanying notes to financial statements.